Vista Pharmaceuticals Ltd Stock Falls to 52-Week Low of Rs.6.05

Stock Performance and Market Context

On 2 Mar 2026, Vista Pharmaceuticals Ltd (Stock ID: 384463) recorded a day change of -2.46%, extending its losing streak to two consecutive sessions with a cumulative decline of approximately -2.6%. The stock’s current price of Rs.6.05 represents a sharp fall from its 52-week high of Rs.13.09, underscoring a near 54% depreciation over the past year.

In comparison, the Sensex index, despite a volatile session marked by a gap down opening of -2,743.46 points, managed a partial recovery to trade at 80,156.71, down -1.39% on the day. The Sensex’s 50-day moving average remains above its 200-day moving average, signalling a relatively stable market environment contrasting with Vista Pharmaceuticals’ downward trajectory.

Vista Pharmaceuticals is currently trading below all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — indicating sustained bearish momentum. The stock has underperformed its sector by -1.7% today and has delivered a negative return of -28.40% over the last 12 months, while the Sensex gained 9.55% in the same period.

Financial Performance and Fundamental Assessment

Vista Pharmaceuticals’ financial results for the nine months ended December 2025 reveal subdued performance. Net sales stood at Rs.5.40 crores, reflecting a contraction of -21.17% year-on-year. The company reported a net loss (PAT) of Rs.-6.20 crores for the same period, also declining by -21.17%. These figures highlight a challenging revenue environment and continued pressure on profitability.

The company’s operating profit has deteriorated at an annualised rate of -15.56% over the past five years, indicating a prolonged period of weak growth. Additionally, Vista Pharmaceuticals carries a high debt burden relative to its earnings, with a Debt to EBITDA ratio of -1.00 times, signalling limited capacity to service debt obligations effectively.

Over the last year, the company’s profits have plunged by -151.6%, further emphasising the financial strain. This negative EBITDA position contributes to the stock’s classification as a “Strong Sell” with a Mojo Score of 12.0, downgraded from a previous “Sell” rating on 18 Jul 2024. The Market Cap Grade stands at 4, reflecting the company’s relatively modest market capitalisation within its sector.

Comparative Performance and Risk Factors

Vista Pharmaceuticals has consistently underperformed not only the Sensex but also the BSE500 index across multiple time frames, including the last three years, one year, and three months. This below-par performance underscores the stock’s challenges in both the near and long term.

The stock’s risk profile is elevated due to its negative EBITDA and weak fundamental strength. The majority of its shares are held by non-institutional investors, which may contribute to lower liquidity and higher volatility. The Pharmaceuticals & Biotechnology sector, while generally resilient, has seen mixed performances, and Vista Pharmaceuticals’ metrics place it at a disadvantage relative to peers.

Summary of Key Metrics

To summarise, Vista Pharmaceuticals Ltd’s stock has reached a new 52-week low of Rs.6.05, reflecting a sustained downtrend amid weak financial results and deteriorating fundamentals. The company’s net sales and profits have contracted significantly over the recent nine-month period, while its long-term growth trajectory remains negative. The stock’s valuation and risk profile are unfavourable, with a strong sell rating and a low Mojo Grade reinforcing the cautious stance.

Despite the broader market’s partial recovery and the Sensex’s relative strength, Vista Pharmaceuticals continues to face headwinds that have weighed on its share price and investor sentiment. The stock’s position below all major moving averages further confirms the prevailing bearish trend.

Limited Period Only. Start at Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Get 71% Off →